{"title": "Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs", "doi": "10.1101/2020.03.20.999730", "citation_id": "2020.03.20.999730v2", "date": "2020-03-23", "laguage": "en", "journal_title": "bioRxiv", "first_page": "2020.03.20.999730", "abstract": "<p>COVID-19 is an emerging infectious disease and was recently declared as a pandemic by WHO. Currently, there is no vaccine or therapeutic available for this disease. Drug repositioning represents the only feasible option to address this global challenge and a panel of fifty FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection. We found a total of 24 drugs which exhibited antiviral efficacy (0.1 \u03bcM &lt; IC50 &lt; 10 \u03bcM) against SARS-CoV-2. In particular, two FDA-approved drugs \u2013 niclosamide and ciclesonide \u2013 were notable in some respects. These drugs will be tested in an appropriate animal model for their antiviral activities. In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.</p>", "twitter_description": "COVID-19 is an emerging infectious disease and was recently declared as a pandemic by WHO. Currently, there is no vaccine or therapeutic available for this disease. Drug repositioning represents the only feasible option to address this global challenge and a panel of fifty FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection. We found a total of 24 drugs which exhibited antiviral efficacy (0.1 \u03bcM < IC50 < 10 \u03bcM) against SARS-CoV-2. In particular, two FDA-approved drugs \u2013 niclosamide and ciclesonide \u2013 were notable in some respects. These drugs will be tested in an appropriate animal model for their antiviral activities. In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.", "full_text_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.full", "public_url": "https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2", "abstract_html_url": "https://www.biorxiv.org/content/10.1101/2020.03.20.999730v2.abstract", "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/23/2020.03.20.999730.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory", "pisa": "biorxiv;2020.03.20.999730v2", "access_rights": "restricted", "authors": ["Sangeun Jeon", "Meehyun Ko", "Jihye Lee", "Inhee Choi", "Soo Young Byun", "Soonju Park", "David Shum", "Seungtaek Kim"]}